What should you pay attention to when using deuterated colexitinib/sondido?

氘可来昔替尼/颂狄多（Deucravacitinib）是一种新型的靶向药物，主要用于治疗斑块型银屑病。 In clinical studies, the use of deuterated colexitinib has caused some side effects and precautions that require caution, and these adverse reactions may affect patients' treatment options and health status. During the use of deuterated colexitinib, medical staff need to pay special attention to the following aspects.

1. Allergic reaction is one of the common side effects of deuterated coxitinib treatment.临床观察显示，部分患者在使用该药物后出现了血管性水肿、皮疹等超敏反应现象。 If a patient develops a clinically significant allergic reaction, physicians should immediately take appropriate treatment measures and review the patient's medication records to determine whether deuterated colexitinib needs to be discontinued. The management of allergic reactions is crucial to ensuring patient safety, and medical staff need to pay close attention to possible allergic symptoms and respond promptly.

2、感染风险也是临床使用氘可来昔替尼需重点关注的内容。 During the treatment process, patients may face the threat of serious infections, such as pneumonia, new coronavirus pneumonia, etc. Patients with a history of active infection, especially those who are experiencing a severe infection or have a history of chronic infection, should undergo a thorough evaluation before using this drug. Such patients must closely monitor changes in infection symptoms while taking deuterated colexitinib. Once a new infection occurs, timely diagnosis and anti-infective treatment should be initiated.

3. In terms of tuberculosis, the use of deuterated coxitinib requires caution. All patients who are about to start treatment with this drug must be evaluated for tuberculosis infection, especially the risk of latent or active tuberculosis infection. The use of deuterated colexitinib is absolutely contraindicated in patients with confirmed active pulmonary tuberculosis. For patients with a history of latent tuberculosis, anti-tuberculosis treatment is recommended before starting treatment with deuterated colexitinib to reduce the risk of tuberculosis recurrence. At the same time, medical staff should regularly monitor patients for tuberculosis-related symptoms during treatment.

4. The occurrence of malignant tumors is also a major concern in the use of deuterated colexitinib. Studies have shown that deuterated colexitinib may be associated with a risk of certain types of malignancy, particularly in patients with a known history of malignancy. Before initiating or continuing treatment with deuterated colexitinib, health care providers should carefully evaluate the risks and benefits of the patient, especially those with a history of previous cancer, and carefully consider the use of the drug.

5. Deuterated colexitinib may cause rhabdomyolysis and increased levels of creatine kinase (CPK). Cases of rhabdomyolysis have occurred in treated patients, resulting in interruption or cessation of treatment. If a patient exhibits elevated CPK levels or clinical suspicion of myopathy, deuterated colexitinib must be discontinued immediately. At the same time, patients should be instructed to report any unexplained muscle pain or weakness during treatment so that it can be addressed promptly.

6. Management of immunizations during treatment with deuterated colexitinib. Before starting treatment, patients should receive age-appropriate vaccinations according to relevant immunization guidelines, including preventive herpes zoster vaccine. At the same time, the use of live vaccines should be avoided during treatment with deuterated colexitinib because its effects on the immune system are unknown.

7. andThe potential risks associated with JAK inhibition are also clinical issues that require attention. Although deuterated coxitinib mainly targets the inhibition of TYK2, the correlation between its potential adverse reactions and JAK inhibition still requires further study. Clinical data suggest that patients receiving JAK inhibitor therapy may be at increased risk of all-cause mortality, particularly cardiovascular events. Therefore, during the use of deuterated colexitinib, medical staff should regularly assess the patient's cardiovascular health status to ensure patient safety.

In summary, deuterated colexitinib, as an emerging treatment option, has potential efficacy, but its related side effects and risks cannot be ignored. Medical staff need to comprehensively assess the patient's health status, formulate an individualized treatment plan, and conduct close monitoring during the treatment process to ensure patient safety and treatment effectiveness. Through scientific and reasonable management and monitoring, the occurrence of adverse reactions can be minimized and help patients obtain the best treatment results.

Reference materials:https://go.drugbank.com/drugs/DB16650